

Buchanan Ingersoll

ATTORNEYS

Edward John Allera
202 452 7985
alleraej@bipc.com

1776 K Street, N.W.
Suite 800
Washington, DC 20006-2365

T 202 452 7900
F 202 452 7989
www.buchananingersoll.com

September 8, 2003

Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD, 20852

Notice of Participation

Docket No. 2003N-0324

Under 21 CFR part 12, please enter the participation of:

Andrew L. Winstrom, President
Pennfield Oil Co. / Pennfield Animal Health Co.
14040 Industrial Road
Omaha, Nebraska 68144
(402) 330-6000


Service on the above will be accepted by:

Edward John Allera, Esq.
Counsel to Pennfield Oil Co. / Pennfield Animal
Health Co.
Buchanan Ingersoll
1776 K Street, Suite 800
Washington, D.C. 20006
(202) 452-7985


The following statements are made as part of this notice of participation:

A. *Specific interests.* Pennfield Oil Co./ Pennfield Animal Health Co. ("Pennfield") markets combination oxytetracycline and neomycin, an animal drug product at issue in "Certain Antibiotic New Animal Drug Products and Use Combinations Subject to Listings in the New Animal Drug Regulations; Drug Efficacy Study Implementation; Notice of Opportunity for Hearing," published in the *Federal Register* on August 8, 2003 (68 Fed. Reg. 47332), and desires to be heard regarding all matters pertaining to the legal regulatory status of its product, (NADA 138-939).

B. *Commitment to participate.* "Pennfield" will present documentary evidence and/or testimony at the hearing, will otherwise fully participate in the hearing process, and will comply with the requirements of 21 CFR 12.85.



Andrew L. Winstrom, President
Pennfield Oil Co. and Pennfield Animal
Health Co.



Edward John Allera, Counsel to Pennfield
Oil Co. and Pennfield Animal Health Co.